A new surge in infections in China amid the Delta variant and an emergency approval in the US appear to have renewed Chinese bioventure executives’ interest in developing antibody therapies against COVID-19.
The US Food and Drug Administration on 30 July revised the November 2020 emergency use authorization (EUA) for Regeneron...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

